X4 Pharmaceuticals, Inc. (XFOR): Price and Financial Metrics
GET POWR RATINGS... FREE!
XFOR Stock Price Chart Interactive Chart >
XFOR Price/Volume Stats
| Current price | $1.65 | 52-week high | $6.18 |
| Prev. close | $1.49 | 52-week low | $0.86 |
| Day low | $1.50 | Volume | 1,772,813 |
| Day high | $1.86 | Avg. volume | 429,351 |
| 50-day MA | $1.16 | Dividend yield | N/A |
| 200-day MA | $1.49 | Market Cap | 113.27M |
X4 Pharmaceuticals, Inc. (XFOR) Company Bio
X4 Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company specializes in developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases including primary immunodeficiencies and cancer. X4's oral small molecule drug candidates antagonize the CXCR4 pathway which plays a central role in immune surveillance.
Latest XFOR News From Around the Web
Below are the latest news stories about X4 PHARMACEUTICALS INC that investors may wish to consider to help them evaluate XFOR as an investment opportunity.
H.C. Wainwright Sticks to Their Buy Rating for X4 Pharmaceuticals (XFOR)In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on X4 Pharmaceuticals (XFOR - Research Report), with a price target of $3.50. The company's shares opened today at $1.25.Ramakanth covers the Healthcare sector, focusing on stocks such as Mediwound, X4 Pharmaceuticals, and ImmunoGen. According to TipRanks, Ramakanth has an average return of -14.7% and a 27.92% success rate on recommended stocks. Currently, the analyst consensus on X4 Pharmaceuticals is a Strong Buy with an average price target of $5.50, implying a 340.00% upside from current levels. In a report released yesterday, Brookline Capital Markets also maintained a Buy rating on the stock with a $6. |
X4 Pharmaceuticals (XFOR) Receives a Buy from B.Riley FinancialB.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on X4 Pharmaceuticals (XFOR - Research Report) today and set a price target of $7.00. The company's shares opened today at $1.05.Mamtani covers the Healthcare sector, focusing on stocks such as Novavax, Altimmune, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -31.7% and a 19.48% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for X4 Pharmaceuticals with a $5.50 average price target, implying a 423.81% upside from current levels. |
Analysts Offer Insights on Healthcare Companies: X4 Pharmaceuticals (XFOR) and Avidity Biosciences (RNA)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on X4 Pharmaceuticals (XFOR – Research Report) and Avidity Biosciences (RNA – Research Report) with bullish sentiments. X4 Pharmaceuticals (XFOR) In a report released today, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on X4 Pharmaceuticals, with a price target of $6.50. The company's shares closed last Tuesday at $1.04, close to its 52-week low of $0.86. According to TipRanks. |
X4 Pharma Highlights New Data Supporting Mavorixafor's Broad Potential In Chronic NeutropeniaX4 Pharmaceuticals Inc (NASDAQ: XFOR) announced new data from its Phase 1b trial evaluating the ability of its lead clinical candidate, mavorixafor, to increase the absolute neutrophil count (ANC) in chronic neutropenia (CN) patients as monotherapy or concurrently with injectable granulocyte colony-stimulating factor (G-CSF). People with CN have a lower number of neutrophils, a type of white blood cell, for more than three months. 100% of study participants (n=25) responded to treatment with a s |
X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor’s Broad Potential in Chronic Neutropenia (CN)100% of study participants (n=25) achieved robust responses to oral mavorixafor 100% of neutropenic participants (n=14) achieved normalized neutrophil counts Robust responses achieved across all CN disorders studied (idiopathic, cyclic, congenital); estimated diagnosed patient population ~ 50,000 in the U.S. Results suggest mavorixafor could be the first oral treatment for CN disorders and has the potential to reduce or replace injectable G-CSF, the current standard of care X4 to host investor w |
XFOR Price Returns
| 1-mo | 66.65% |
| 3-mo | 58.65% |
| 6-mo | -12.70% |
| 1-year | -68.81% |
| 3-year | -86.84% |
| 5-year | N/A |
| YTD | -27.95% |
| 2021 | -64.39% |
| 2020 | -39.91% |
| 2019 | -23.13% |
| 2018 | -81.82% |
| 2017 | N/A |
Continue Researching XFOR
Want to see what other sources are saying about X4 Pharmaceuticals Inc's financials and stock price? Try the links below:X4 Pharmaceuticals Inc (XFOR) Stock Price | Nasdaq
X4 Pharmaceuticals Inc (XFOR) Stock Quote, History and News - Yahoo Finance
X4 Pharmaceuticals Inc (XFOR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...